iScience (Nov 2022)

Defining the origin, evolution, and immune composition of SDH-deficient renal cell carcinoma

  • Joana B. Neves,
  • Kirsty Roberts,
  • Janani Sivakumaran Nguyen,
  • Soha El Sheikh,
  • My-Anh Tran-Dang,
  • Catherine Horsfield,
  • Faiz Mumtaz,
  • Peter Campbell,
  • Hans Stauss,
  • Maxine G.B. Tran,
  • Thomas Mitchell

Journal volume & issue
Vol. 25, no. 11
p. 105389

Abstract

Read online

Summary: Succinate dehydrogenase (SDH)-deficient renal cell carcinoma represents a rare subtype of hereditary kidney cancer. Clinical diagnosis can be challenging and there is little evidence to guide systemic therapeutic options. We performed genomic profiling of a cohort of tumors through the analysis of whole genomes, transcriptomes, as well as flow cytometry and immunohistochemistry in order to gain a deeper understanding of their molecular biology. We find neutral evolution after early tumor activation with a lack of secondary driver events. We show that these tumors have epithelial derivation, possibly from the macula densa, a specialized paracrine cell of the renal juxtaglomerular apparatus. They subsequently develop into immune excluded tumors. We provide transcriptomic and protein expression evidence of a highly specific tumor marker, PAPPA2. These translational findings have implications for the diagnosis and treatment for this rare tumor subtype.

Keywords